To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. (June 2019) - Martin, Peter; Goy, Andre; Ramchandren, Radhakrishnan; Ferrante, Lucille; Londhe, Anil; McGowan, Tracy; Bartlett, Nancy L